All In Biotech

Drug Trial Radar · NCT01000974

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

Phase III, Partially Double-blind Study to Evaluate Consistency and Immunogenicity of 3 Lots of GSK Biologicals' Hib Conjugate Vaccine 208108 Versus ActHIB and Pentacel at 2, 4, 6 and 15-18 Months of Age in Healthy Infants

Last checked: Nov 19, 2026Latest source record: Jul 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,003 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,003

Actual

Start

Jun 18, 2010

Primary completion

Nov 18, 2011

Study completion Jul 17, 2013

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
Who can join
All sexes, from 6 weeks, up to 12 weeks
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety, to demonstrate lot-to-lot consistency of the vaccine, to address the relevant concomitant vaccine administrations and to provide a comparison between GSK Biologicals' Hib conjugate vaccine and the licensed monovalent Hib vaccine ActHIB as well as the licensed combination product Pentacel in infants at 2, 4, 6 and 15-18 months of age. This study is designed with a primary and a booster phase.

Conditions

  • Haemophilus Influenzae Type b

Interventions

  • GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)Biological

    Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.

  • ActHIB™Biological

    Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination

  • Pentacel™Biological

    Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination

  • Pediarix™Biological

    Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection

  • Prevnar 13™Biological

    Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection

  • Rotarix™Biological

    Two oral doses in primary epoch at 2 and 4 months of age

  • Engerix™-BBiological

    Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection

  • Infanrix™Biological

    One dose in the booster epoch at 15-18 months of age as intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations Greater Than or Equal to (≥) 0.15 Microgram Per Milliliter (µg/mL) and ≥ 1.0 µg/mLTime frame: At 1 month after last dose of primary vaccination
  2. Number of Subjects With Anti-Protein-D (Anti-D) and Anti-Protein-T (Anti-T) Antibody Concentrations ≥ 0.1 International Units Per Milliliter (IU/mL)Time frame: At 1 month after last dose of primary vaccination
  3. Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody ConcentrationsTime frame: At 1 month after last dose of primary vaccination
  4. Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA) Antibody ConcentrationsTime frame: At 1 month after last dose of primary vaccination
  5. Anti-Streptococcus Pneumoniae (S.Pneumoniae) Antibody ConcentrationsTime frame: At 1 month after last dose of primary vaccination
  6. Number of Subjects With Seroresponse (95%) to Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Hemagglutinin (Anti-FHA)Time frame: At 1 month after last dose of primary vaccination
  7. Number of Subjects With Anti-Polio 1,2,3 Antibody Titres Greater Than or Equal to Cut-off ValueTime frame: At 1 month after last dose of primary vaccination
  8. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations ≥ 1.0 µg/mLTime frame: At 1 month after booster vaccination

Locations

63 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Dothan, Alabama

  • GSK Investigational Site

    Benton, Arkansas

  • GSK Investigational Site

    Fayetteville, Arkansas

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Antioch, California

  • GSK Investigational Site

    Daly City, California

  • GSK Investigational Site

    Fountain Valley, California

  • GSK Investigational Site

    Fremont, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Hayward, California

  • GSK Investigational Site

    Huntington Beach, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    Redwood City, California

  • GSK Investigational Site

    Roseville, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    Santa Clara, California

  • GSK Investigational Site

    Santa Rosa, California

  • GSK Investigational Site

    Vallejo, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    West Covina, California

  • GSK Investigational Site

    Boulder, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Orange City, Florida

  • GSK Investigational Site

    Marietta, Georgia

  • GSK Investigational Site

    Woodstock, Georgia

  • GSK Investigational Site

    Honolulu, Hawaii

  • GSK Investigational Site

    Waipio, Hawaii

  • GSK Investigational Site

    Nampa, Idaho

  • GSK Investigational Site

    Bardstown, Kentucky

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Fall River, Massachusetts

  • GSK Investigational Site

    Stevensville, Michigan

  • GSK Investigational Site

    Saint Paul, Minnesota

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Mineola, New York

  • GSK Investigational Site

    Syracuse, New York

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.